about
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyEvolving treatment paradigms for chemotherapy-induced nausea and vomitingFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingPotential therapeutic targets for neurokinin-1 receptor antagonistsA role for fMRI in optimizing CNS drug development.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Substance P: a new era, a new role.The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Anti-emetics in development.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone.Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.Anti-emetic mechanisms of Zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlatesAprepitant--a novel NK1-receptor antagonist.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Clinical practice guidelines on antiemetics in oncology.Emerging drugs for chemotherapy-induced emesis.Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Supportive care in hemato-oncology: a review in light of the latest guidelines.Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.Gastroparesis: Medical and Therapeutic Advances.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Mode of action of peppermint oil and (-)-menthol with respect to 5-HT3 receptor subtypes: binding studies, cation uptake by receptor channels and contraction of isolated rat ileum.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting.Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective NK-1 receptor antagonist, casopitant (GW679769B).Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.Suppression of Cisplatin-Induced Vomiting by Cannabis sativa in Pigeons: Neurochemical Evidences.The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer
P2860
Q26783177-3E17F076-3C9C-4C7A-B76F-138A66A40053Q27024463-C594C42C-56E7-4ABF-A683-5E4731E7D09BQ28258863-FEC7C6C3-7D2B-4DBB-AC87-A6CC418AB0D9Q28262693-45DDCCBB-9040-4327-ADDD-9DB5CB09AA4CQ31036354-6E8E6A91-40A8-41C3-B434-31043D6D7753Q34327488-179F4D6E-A6EA-4C5B-86C1-57D0FF4B5580Q34371517-807A1B9E-77E5-4AAC-8986-1273768F3B41Q34475975-0DA15026-A19D-48D2-8767-0ABC168EAD50Q34588516-3EDD44D6-4B6B-4A57-9CFF-12F2DC725B0AQ34660860-7DF2ECBA-A318-465A-99ED-727EBDDD8210Q34775395-CC5F2EFF-5067-4A7B-A974-F4B4C7238FD6Q34976200-B16F5658-84AE-446F-8BC1-B6DEDCEF597CQ34987555-7D52455A-C1E3-4642-93B6-4802EC1CA417Q35164623-AC357581-80E1-49C8-A8FF-C998618F2FA6Q35594000-F6F2E537-71FB-43AD-B64F-0403702B59D0Q35779340-0A617975-4421-411F-9962-72567AD12D8CQ35918427-53E8CFD6-1D55-4FD6-8C21-5ED358CE5C0EQ36334870-06D3CDB0-EB62-41DB-9F5F-F8E8DD5D8C58Q36407422-F143C7B6-671C-45FB-8DF7-62B5712E552BQ36673972-2BA8D70F-8CBC-494B-A5B3-C8CC3716B1B5Q37013063-4006DB94-FCE4-4D25-A848-F5F1C3505054Q37316977-3F7019D0-FEBD-42C2-9DBB-BED9CAB8D695Q37570350-E8B7C100-985B-46A2-8E8A-2B852793DC23Q37609798-B2B30BEC-BB41-4797-96FA-4E82517F62C7Q37636064-8978728B-9A17-4F33-8E16-6C02D1921E8AQ37702827-72F2B17F-6E4E-4DCB-821C-D6C5B0AC0F7EQ37902946-295A6B4A-2202-4998-A18F-A7DF447EA230Q38018635-87C07453-ED11-4B43-BA11-1F8073C8A510Q38672906-F0DAD6D6-94F9-4AE9-8051-3D4D340E93CBQ38677762-FB54461D-F3A2-49FF-832D-3B34B1EE7C29Q39631811-847225E6-F2C9-4203-9F86-FA4C46D28DA6Q40542547-54321608-A29E-4697-9410-81D0B53E0A8BQ44925317-49428C3B-CBBB-4CB5-945B-DF7D48B82385Q48116794-3EFA067B-AC86-4FA7-AB53-BC3C5974E58CQ49264439-14AF80A5-0AB5-4F9D-AACB-D32AB96BB45FQ50442516-106EA42C-1301-4AC5-83E7-4090AA0429D5Q51840084-EC92E5F8-8B80-40B3-B052-AC28DC0C29B6Q53239014-5F8D1853-DFE4-4180-8E8E-2CC6C92D196AQ55116566-059A5673-3642-4EE1-8C29-0EA0F2BD263FQ58914868-F5779F7F-79AC-4AA0-BBC2-A8EAE80CD7DF
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Potential of substance P antagonists as antiemetics.
@ast
Potential of substance P antagonists as antiemetics.
@en
type
label
Potential of substance P antagonists as antiemetics.
@ast
Potential of substance P antagonists as antiemetics.
@en
prefLabel
Potential of substance P antagonists as antiemetics.
@ast
Potential of substance P antagonists as antiemetics.
@en
P1433
P1476
Potential of substance P antagonists as antiemetics.
@en
P2093
P304
P356
10.2165/00003495-200060030-00002
P577
2000-09-01T00:00:00Z
P5875
P6179
1053038759